FDA Recalls Tri-Mix Injectable Due to Sterility Assurance Concerns
The Compounding Pharmacy of America is recalling Tri-Mix Injectable due to FDA inspection findings of GMP violations that may impact sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls involving potential sterility issues in injectable drugs are categorized as Severe (Score 4), particularly given the risk of infection associated with non-sterile injectables.
Plain-English summary
The Compounding Pharmacy of America is recalling Tri-Mix (30/1/10) (MFG) Injectable, a 27 ml product manufactured in Knoxville, Tennessee. The recall was initiated because an FDA inspection identified Good Manufacturing Practice (GMP) violations that potentially impact the product's quality and sterility.
The recall covers all lots of the product distributed nationwide between November 2014 and May 2015. Specific lot codes and expiration dates are listed in the official recall documentation. The agency classification for this recall is Class II.
Consumers and healthcare providers who have this product should stop using it and contact the recalling firm or their healthcare provider for instructions on return or disposal. The FDA has not reported specific illnesses or injuries associated with this recall in the provided text.
The recalled product
- Product
- Tri-Mix (30/1/10) (MFG) Injectable, The Compounding Pharmacy of America, Knoxville, TN
- Manufacturer
- The Compounding Pharmacy of America
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- All lots distributed between November 2014 and May 2015
- 12022014@50
- 5/31/2015
- 01092015@31
- 7/8/2015
- 02102015@43
- 8/9/2015
- 03272015@42
- 9/23/2015
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 382 recalled by The Compounding Pharmacy of America under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 382 products in this recall →Related recalls
Same manufacturer · The Compounding Pharmacy of America
See all →- CriticalFDA Recalls Non-Sterile HCG and Methylcobalamin Injection Vials
FDA (Drugs) · 2018-02-21
- SevereFDA Recalls Morphine and Ropivacaine Compounded Solution Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereHydromorphone Solution Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereMorphine and Bupivacaine Solution Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereMethylcobalamin Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFDA Recalls Key Pharmacy Compounded Sterile Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereFDA Recalls Prostaglandin Tri-Mix Injection Due to Sterility Concerns
FDA (Drugs) · 2019-04-24
- SevereKey Pharmacy Recalls TRI MIX Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereFDA Recalls Key Pharmacy Compounded Sterile Injections Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereKey Pharmacy Recalls Sterile Compounded Injection Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereMontana Compounding Pharmacy Recalls Trimix Injectable Due to Sterility Concerns
FDA (Drugs) · 2015-06-17